Toggle navigation
Home
Search
Services
Blog
Contact
About
Cardiovascular Molecular Prognostic Kits
Bentley, Kevin L.
Genaissance Pharmaceuticals, Inc., New Haven, CT, United States
Search 4 grants from Kevin Bentley
Search grants from Genaissance Pharmaceuticals, Inc.
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Comments
Recent in Grantomics:
University of Medicine & Dentistry of NJ
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
P20 Exploratory Center for Precision Health in Diverse Populations
Profiles of Working Memory for Educational Research
P20 Exploratory Center for Precision Health in Diverse Populations
P20 Exploratory Center for Precision Health in Diverse Populations
Ig Gene Regulation: Targeting Cis and Trans Components
Recently added grants:
New Synthetic Methods Enabled by Excited-State Redox Chemistry
Calmodulin-dependent regulation of cardiac ryanodine receptor
Photoredox Catalysis Applications in Organometallics and Chemical Biology
Reprogramming of mature smooth muscle cells to vascular progenitor cells
Mechanisms of Human DNA Double-Strand Break Repair via Quantitative Single-Molecule Imaging
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
5R44HL059114-03
Application #
2750644
Study Section
Special Emphasis Panel (ZRG2-SSS-Y (15))
Project Start
1997-08-29
Project End
1999-07-31
Budget Start
1998-09-10
Budget End
1999-07-31
Support Year
3
Fiscal Year
1998
Total Cost
Indirect Cost
Institution
Name
Genaissance Pharmaceuticals, Inc.
Department
Type
DUNS #
City
New Haven
State
CT
Country
United States
Zip Code
06511
Related projects
NIH 1998
R44 HL
Cardiovascular Molecular Prognostic Kits
Bentley, Kevin L. / Genaissance Pharmaceuticals, Inc.
NIH 1997
R44 HL
Cardiovascular Molecular Prognostic Kits
Bentley, Kevin L. / Genaissance Pharmaceuticals, Inc.
Comments
Be the first to comment on Kevin Bentley's grant